TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04702425
Drug: VOB560
Normalized name: VOB560
DrugBank: S65487 (DB17556)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for concentrate for solution for infusion
Study: NCT04702425
Drug: MIK665
Normalized name: MIK665
DrugBank: S64315 (DB17559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate for solution for infusion
Study: NCT04654078
Drug: IN-C004 with water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dose of IN-C004 taken with water
Study: NCT04654078
Drug: IN-C004 without water
Normalized name: ethanol
DrugBank: Water (DB09145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One time dose of IN-C004 taken without water
Study: NCT04654078
Drug: K-CAB tab. with water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dose of K-CAB tab. taken with water
Study: NCT06261359
Drug: CEND-1
Normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEND-1 will be provided as concentrate for solution to be administered via IV injection.
Study: NCT06261359
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be provided as solution to be administered via IV infusion.
Study: NCT06261359
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel will be provided as solution to be administered via IV infusion.
Study: NCT05157139
Drug: Oral Capsule
Normalized name: Oral Capsule
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Capsule of vanillin \& wheat germ oil
Study: NCT05829655
Drug: Drug D (Blinded Drug)
Normalized name: Lenti-d drug product
DrugBank: Elivaldogene tavalentivec (DB19095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Study: NCT05829655
Drug: Suvorexant (20mg/day)
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double blind administration of suvorexant once per day during residential stay until discharge.
Study: NCT06450132
Drug: Atropine Ophthalmic
Normalized name: atropine ophthalmic
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.05% atropine ophthalmic solution
Study: NCT05974449
Drug: Vaginal Lactobacillus capsules
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This product is a micro-ecological preparation made from live Lactobacillus and is used for the treatment of vaginosis caused by disorders of the flora.
Study: NCT06140537
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10mg orally daily
Study: NCT05252923
Drug: Sulodexide
Normalized name: sulodexide
DrugBank: Sulodexide (DB06271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide 250 LSU 1 oral capsule twice daily for 8 weeks
Study: NCT04965038
Drug: Alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous thrombolysis with alteplase within 4.5 hours of symptom onset
Study: NCT05314933
Drug: 2-Deoxyglucose
Normalized name: 2-DEOXYGLUCOSE
DrugBank: 2-deoxyglucose (DB08831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal administration
Study: NCT00002020
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05099159
Drug: Elinzanetant (BAY3427080)
Normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg elinzanetant orally once daily
Study: NCT06221748
Drug: Disitamab Vedotin Injection
Normalized name: Brentuximab Vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase II and III study ：2.5mg/kg, intravenous infusion，D1, every 2 weeks
Study: NCT06221748
Drug: Cadonilimab Injection
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase II and III study ：6.0mg/kg, intravenous infusion，D1, every 2 weeks.
Study: NCT06221748
Drug: Paclitaxel Injection
Normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase II and III study ：Calculate dosage based on body surface are,160mg/m2,intravenous infusion，D1,D8 every 3 weeks
Study: NCT05503888
Drug: Almonertinib combined with SHR-1701
Normalized name: miconazole
DrugBank: Almonertinib (DB16640)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase Ⅰb/Phase Ⅱ：~SHR-1701: injection, intravenous infusion~Almonertinib: tablets, oral
Study: NCT05503888
Drug: Almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase Ⅱ:~Almonertinib: tablets, oral
Study: NCT05633966
Drug: Kisspeptin 112-121
Normalized name: Kisspeptin
DrugBank: Kisspeptin (DB19112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)
Study: NCT05934331
Drug: LM302+Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LM-302 in combination with Toripalimab.
Study: NCT05040360
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05840588
Drug: Antibiotic Treatment
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic Amoxicillin or Amoxicillin/Clavulanic acid
Study: NCT06158113
Drug: Baricitinib 4 milligram Oral Tablet
Normalized name: baricitinib 4 MG
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 milligrams once daily
Study: NCT06304779
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine group receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively and Control group receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.~Both groups will receive the same anesthesia and postoperative analgesia protocols, lung-protective ventilation strategy, and fluid, transfusion, and warming strategies. The only difference is the intervention during surgery, with the lidocaine group receiving continuous intravenous lidocaine.
Study: NCT05790720
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients older than 65 years of age will receive an intravenous infusion of Propofol with prespecified plasma targets. During its administration, registration of BIS values, frontal electroencephalography, and clinical signs of consciousness will be performed.
Study: NCT04088591
Drug: Dextrose in Water
Normalized name: dextrose in water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of 5% dextrose in water every 6 hours for a total duration of 96 hours
Study: NCT04768400
Drug: Arm I (MEP)
Normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.
Study: NCT05614648
Drug: Clonidine Micropellets
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.975 mg clonidine hydrochloride as 3 micropellets administered in one injection
Study: NCT06383468
Drug: AK120
Normalized name: Abiraterone acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300mg Q2W subcutaneous injection thereafter until week 50.
Study: NCT04794127
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
Study: NCT04794127
Drug: Pioglitazone Oral Product
Normalized name: pioglitazone Oral Product
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
Study: NCT00051584
Drug: SGN-15 (cBR96-Doxorubicin Immunoconjugate)
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: SGN-15 (DB05818)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05446571
Drug: Letermovir
Normalized name: Letermovir
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maternal daily administration of 240 milligrams of letermovir (1x240 mg-tablets) up-until delivery or TOP Placebo of Valaciclovir ; daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP
Study: NCT05446571
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP Placebo of letermovir : (1x240 mg-tablets) up-until delivery or TOP
Study: NCT00051584
Drug: Gemzar (Gemcitabine)
Normalized name: gemcitabine Injection [Gemzar]
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05541445
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The subjects first receive induction therapy with pembrolizumab combined with chemotherapy for 6 weeks, and then receive sequential therapy with pembrolizumab combined with concurrent chemoradiotherapy for 6 weeks, and receive surgical treatment within 4-8 weeks after neoadjuvant therapy. For patients whose postoperative pathology is confirmed as PCR (pathological complete response), the patients will be observed with long-time follow-up; If the postoperative pathology is confirmed as non-PCR, pembrolizumab will be administrated until 1 year or disease progression or intolerable toxicity.
Study: NCT00002112
Drug: Nystatin
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002112
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05521789
Drug: ESB Thoracic
Normalized name: Esbriet
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Erector spinae thoracic block with bupivacaine
Study: NCT06423846
Drug: sevoflurane group
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For patients in the SEVO group, general anesthesia was induced with propofol 2 mg/kg, fentanyl 1 ug/kg and then maintained with sevoflurane in air and oxygen, dexmedetomidine 1 ug/kg/hour.
Study: NCT00690911
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations.
Study: NCT04840550
Drug: Lansoprazole 15 mg
Normalized name: lansoprazole 15 MG
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 15 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
Study: NCT04840550
Drug: Tegoprazan 25 mg
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 25 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
Study: NCT04648189
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
Study: NCT05946005
Drug: honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tresno Joyo honey applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: MD252109001219
Study: NCT05946005
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolones cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: DKL0922246629AI
Study: NCT05946005
Drug: povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betadine cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: PKD20501710037
Study: NCT05923190
Drug: Enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles
Study: NCT05923190
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered on day 1 of a 21-day cycle
Study: NCT05178862
Drug: SCY-078
Normalized name: SCY-635
DrugBank: SCY-635 (DB12451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibrexafungerp (SCY-078) as step-down therapy.
Study: NCT05178862
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole (SCY-078) as step-down therapy.
Study: NCT04629027
Drug: Immune checkpoint inhibitor
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patients receive necessary treatment without special intervention
Study: NCT05849519
Drug: Coenzyme I for Injection + conventional treatment
Normalized name: iobenguane I-131 Injection
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group used Coenzyme I for injection and conventional treatment for 7 consecutive days
Study: NCT04377152
Drug: 68Gallium-PSMA-11
Normalized name: Gallium Ga 68 PSMA-11
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PSMA-11 Ga 68 Injection is a positron emitting radiopharmaceutical containing radioactive 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11), which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET).
Study: NCT05667220
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin monotherapy group (Group A): 20 eligible patients were planned to be included and given Sitagliptin 100 mg Qd orally; the treatment period was 1 week.
Study: NCT05667220
Drug: Sitagliptin combined with Beidougen capsule
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin combined with Beidougen capsule treatment group (Group B): 20 eligible patients were planned to be included and given sitagliptin 100mg Qd orally combined with Beidougen capsule 60mg Tid orally. The treatment period was 1 week.
Study: NCT05954767
Drug: IS-001
Normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV injection of IS-001 drug substance with near infrared (NIR) imaging
Study: NCT05930236
Drug: Lidocain
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linisol infiltration with depomedrol and omnipaque
Study: NCT05930236
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infiltration with linisol and omnipaque
Study: NCT05930236
Drug: Omnipaque
Normalized name: Omnipaque 9
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infiltration with linisol and methylprednisolone
Study: NCT04826016
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin: 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate). Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
Study: NCT04826016
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel: 100 mg/m2. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
Study: NCT05126628
Drug: Proxalutamide
Normalized name: Proxalutamide
DrugBank: Proxalutamide (DB16065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxalutamide 300mg q.d.(3 tablets of 100mg each) for 14 days.
Study: NCT05188495
Drug: trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy； TPC:treatment of physician's choice,include taxanes，Gemcitabine, capecitabine, vinorelbine
Study: NCT00002153
Drug: A-007
Normalized name: camphor 0.007 MG/MG
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05940532
Drug: Sugemalimab and Chemotherapy
Normalized name: cytarabine and daunorubicin
DrugBank: Sugemalimab (DB16641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC; intravenous infusion every 3 weeks, for up to four cycles.~Sugemalimab: 1200 mg by intravenous infusion every 3 weeks, for up to 2 years.
Study: NCT05900973
Drug: Darolutamide Oral Tablet [Nubeqa]
Normalized name: darolutamide Oral Tablet [Nubeqa]
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral use of Darolutamide as an Inducer of Increased Expression of Prostate-specific membrane antigen (PSMA) in patients with Localized prostate cancer
Study: NCT05408026
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab (and hyaluronidase) will be given over 3-5 minutes subcutaneously (under the skin) in the clinic at alternating left/right abdominal sites. Patient will take dexamethasone orally (by mouth) either before coming to clinic or in clinic, before other medications.~Only for the first cycle, patient will receive on Day 1 daratumumab (which is mixed with a compound called hyaluronidase) and dexamethasone, 1 day before patient start the other 2 medications.
Study: NCT05408026
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On day 2 of cycle 1, patient will start the other medications and will therefore receive bortezomib administered subcutaneously (SC) over 3-5 minutes and dexamethasone given orally (by mouth), either before coming to clinic or in clinic, before bortezomib. Patient will also start pomalidomide on the same day, which patient will take that evening at home and every evening for 21 days.
Study: NCT06088264
Drug: BMS-986322
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days.
Study: NCT06432166
Drug: 2-hydroxybenzylamine acetate
Normalized name: hydroxybenzopyridine
DrugBank: Benzylamine (DB02464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hydroxybenzylamine acetate (2-HOBA) is taken three times per day for 16 weeks
Study: NCT04628988
Drug: CC-90011
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT04628988
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04628988
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT05377580
Drug: Period 2 IBI112 dose 3
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injections
Study: NCT05377580
Drug: Period 1 IBI112 dose 1
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Injection
Study: NCT04332796
Drug: Chorhexidine scrub
Normalized name: chlorhexidine Medicated Liquid Soap [Scrub-Stat]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chorhexidine scrub was given to patients for 4 weeks
Study: NCT05968651
Drug: Oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single acute administration of 24 international units (IU) oxytocin
Study: NCT04730050
Drug: TT-01025-CL
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05708534
Drug: Belatacept
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Switching from anticalcineurins to belatacept in a cohort of kidney transplant recipients seropositive for CMV
Study: NCT06580236
Drug: Botulinum neurotoxin type A
Normalized name: Botulinum A neurotoxin
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Infusion
Study: NCT05008666
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects.